# Intellia Therapeutics financial and clinical updates > Live situation record from CLSTR: https://clstr.news/situations/intellia-therapeutics-financial-and-clinical-updates > Updated: 2026-08-16T11:46:05.000Z. Sources: 3. Developments: 2. Intellia Therapeutics has reported its second-quarter 2026 financial results, characterized by widening net losses and declining collaboration revenues. The company reported a net loss of $106.6 million, compared to $101.3 million in the same period the previous year, citing increased investments to prepare its gene therapy pipeline for commercial marketing. Revenue from collaborations fell to $7.7 million, missing market expectations of approximately $13 million. Despite these financial shifts, the company reported positive clinical developments, specifically noting that its phase III HALO trial for Lonvo-z showed an “87% reduction in mean monthly HAE attacks compared to a placebo.” Intellia maintains a strong liquidity position, supported by a capital increase in April that provided approximately $195 million in net proceeds. The company expects its rolling BLA to be accepted by the FDA by the end of the year, with a target U.S. launch for Lonvo-z in the first half of 2027. Current cash and marketable securities are expected to provide a runway into at least 2028. ## Timeline ### 2026-08-16: Intellia Therapeutics reports $106.6 million Q2 net loss Intellia Therapeutics reported a $106.6 million net loss for Q2 2026 due to increased commercialization investments, though liquidity is secured through 2028. 3 sources. https://clstr.news/cluster/intellia-therapeutics-reports-1066-million-q2-net-loss ### 2026-08-07: Intellia and Vera Therapeutics report earnings and leadership updates Intellia Therapeutics reported Q2 earnings meeting EPS estimates and successful Phase III HALO trial results, while Vera Therapeutics announced new equity awards for its Chief Regulatory Officer. 2 sources. https://clstr.news/cluster/intellia-and-vera-therapeutics-report-earnings-and-leadership-updates --- Cite as: Intellia Therapeutics financial and clinical updates. CLSTR, https://clstr.news/situations/intellia-therapeutics-financial-and-clinical-updates